Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Agreement
Nxera Assigns Cenerimod Japan & APAC Rights to Viatris
Details : Under the agreement, Viatris will hold the right of ACT-334441 (cenerimod) for the development and commercialization. It is a clinical-stage candidate evaluated for autoimmune diseases.
Product Name : ACT-334441
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
February 27, 2025
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Idorsia and Viatris Update their Collaboration for Selatogrel and Cenerimod
Details : The collaboration aims for the global development and commercialization rights to ACT-246475 (selatogrel), a reversible, and selective 2-phenylprimdine-4-carboxamide and ACT-334441 (cenerimod).
Product Name : ACT-334441
Product Type : Other Small Molecule
Upfront Cash : $350.0 million
February 26, 2025
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ACT-334441 (cenerimod), is a highly selective S1P1 receptor modulator, being investigated as an oral once-daily tablet. Cenerimod potentially offers a novel approach for the treatment of SLE, a disease with a significant impact on patients and limited tr...
Product Name : ACT-334441
Product Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cenerimod 4 mg showed clinically meaningful improvement in mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect seen on biological activity. Cenerimod, novel S1P1 receptor modulator an oral treatment of systemic...
Product Name : ACT-334441
Product Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : Cenerimod
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable